Treatment of severe CNS lupus with intravenous immunoglobulin

Citation
G. Engel et Rf. Van Vollenhoven, Treatment of severe CNS lupus with intravenous immunoglobulin, JCR-J CLIN, 5(4), 1999, pp. 228-232
Citations number
25
Categorie Soggetti
Rheumatology
Journal title
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
ISSN journal
10761608 → ACNP
Volume
5
Issue
4
Year of publication
1999
Pages
228 - 232
Database
ISI
SICI code
1076-1608(199908)5:4<228:TOSCLW>2.0.ZU;2-1
Abstract
We present a case of a 20-year-old woman admitted with new onset severe sys temic lupus erythematosus (SLE) with multiple manifestations, including lup us nephritis with renal failure and significant central nervous system (CNS ) lupus. She presented with a forbidding condition and deteriorated despite a regimen of high dose corticosteroids and cyclophosphamide administration . She had progressive CNS disease initially, with multiple generalized toni c-clonic seizures and later with dense left sided hemiparesis. After treatm ent with high dose intravenous immunoglobulin (MG), there was remarkable im provement in overall lupus disease activity and resolution of neurologic de ficits. A head magnetic resonance imaging (MRI) scan early in her hospital course revealed multiple areas of vasogenic and cortical edema consistent w ith ischemic changes, possibly from lupus vasculitis. A repeat MRI after IV IG treatment revealed dramatic interval improvement and resolution of most of the multifocal areas of signal abnormality. The use of IVIG has been reported in a variety of autoimmune disorders, and there have also been several case reports of the successful use of IVIG in the treatment of SLE. IVIG seems to be a relatively safe treatment alterna tive and may have a promising role in the future of lupus treatment. We hav e found only five case reports in the literature specifically involving the use of IVIG in CNS lupus, but they show substantial benefits. Our case is unique because the demonstration of dramatic response to IVIG by a head MRI has not previously been reported, Based on the available information and t he observations in this case, IVIG remains an experimental but promising tr eatment option for patients with SLE.